The estimated Net Worth of Antoine Awad is at least $576 Thousand dollars as of 2 April 2024. Mr Awad owns over 372 units of Synlogic Inc stock worth over $46,725 and over the last 4 years he sold SYBX stock worth over $10,870. In addition, he makes $518,424 as Chief Operating Officer at Synlogic Inc.
Mr has made over 3 trades of the Synlogic Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 372 units of SYBX stock worth $644 on 2 April 2024.
The largest trade he's ever made was selling 6,438 units of Synlogic Inc stock on 3 April 2023 worth over $3,734. On average, Mr trades about 1,577 units every 122 days since 2021. As of 2 April 2024 he still owns at least 33,859 units of Synlogic Inc stock.
You can see the complete history of Mr Awad stock trades at the bottom of the page.
Antoine Awad is the Chief Operating Officer at Synlogic Inc.
As the Chief Operating Officer of Synlogic Inc, the total compensation of Mr Awad at Synlogic Inc is $518,424. There are 2 executives at Synlogic Inc getting paid more, with Aoife Brennan having the highest compensation of $1,793,870.
Mr Awad is 41, he's been the Chief Operating Officer of Synlogic Inc since . There are 15 older and 1 younger executives at Synlogic Inc. The oldest executive at Synlogic Inc is Richard Shea, 68, who is the Independent Director.
Antoine's mailing address filed with the SEC is C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE, MA, 02142.
Over the last 7 years, insiders at Synlogic Inc have traded over $330,991 worth of Synlogic Inc stock and bought 17,000 units worth $31,190 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Synlogic Inc executives and independent directors trade stock every 132 days with the average trade being worth of $7,257. The most recent stock trade was executed by Mary Beth Dooley on 2 April 2024, trading 188 units of SYBX stock currently worth $325.
at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre
Synlogic Inc executives and other stock owners filed with the SEC include: